The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: Simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients

Drug Metabolism and Disposition

Volumn 32, Issue 12, 2004, Pages 1421-1425

  Kuypers, Dirk R J ^a   Claes, Kathleen ^a   Evenepoel, P ^a   Maes, B ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CYTOCHROME P450 3A; GLYCOPROTEIN P; OCTANOIC ACID; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREATH ANALYSIS; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXPOSURE; FEMALE; GASTROINTESTINAL TRACT; HUMAN; KIDNEY ALLOGRAFT; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECIPIENT; STOMACH EMPTYING; STOMACH MOTILITY;

ADMINISTRATION, ORAL; AREA UNDER CURVE; BREATH TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC EMPTYING; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OCTANOIC ACIDS; TACROLIMUS;

STAPHYLOCOCCUS PHAGE 3A;

EID: 9444274955     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001503     Document Type: Article

References (28)

1. Anglicheau D, Verstuyft C, Laurant-Puig P, Becquemont L, Schlageter MH, and Cassinat B (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14:1889-1896.
2. Bekersky I, Dressler D, and Mekki Q (2001a) Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 41:176-182.
3. Bekersky I, Dressler D, and Mekki Q (2001b) Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 41:289-297.
4. Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schäfer A, and van Hooff J (1998) Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc 30:1271-1273.
5. Christians U, Jacobsen W, Benet LZ, and Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41:813-851.
6. Costa A, Alessiani M, De Ponti F, Spada M, Merli M, Zanola S, Barbera D, Rademacher J, Drivas E, and Crema A (1996) Stimulatory effect of FK506 and erythromycin on pig intestinal motility. Transplant Proc 28:2571-2572.
7. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, and Lindemans J (2003) Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
8. Kaus L, Gillespie W, Hussain A, and Amidon G (1999) The effect of in vitro dissolution, gastric emptying rate and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharm Res (NY) 16:272-280.
9. Kimikawa M, Kamoya K, Toma H, and Teraoka S (2001) Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 15:324-329.
10. Kuypers DRJ, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, and Vanrenterghem Y (2004a) Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 43:741-762.
11. Kuypers DRJ, Claes K, Evenepoel P, Maes B, and Vanrenterghem Y (2004b) Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 75:434-447.
12. Maes B, Evenepoel P, Kuypers D, Geypens B, Ghoos Y, and Vanrenterghem Y (2003) Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. Clin Transplant 17:171-176.
13. Maes B, Ghoos Y, Geypens B, Hiele M, Rutgeerts P, and Vantrappen G (1994) Combined carbon-13-glycine/carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids. J Nucl Med 35:824-831.
14. Maes B, Ghoos Y, Hiele M, and Rutgeerts P (1997) Gastric emptying rate of solids in patients with nonulcer dyspepsia. Dig Dis Sci 42:1158-1162.
15. Maes B, Vanwalleghem J, Kuypers D, Ghoos Y, Rutgeerts P, and Vanrenterghem Y (1999) Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Transplantation 68:1482-1485.
16. Mancinelli L, Frassetto L, Floren L, Dressler D, Carrier S, Bekersky I, and Benet L (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69:24-31.
17. Margreiter R, for the European Tacrolimus vs Ciclosporin-Microemulsion Renal Transplantation Study Group (2002) Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomized multicentre study. Lancet 359:741-746.
18. Satoh S, Tada H, Tachiki Y, Tsuchiya N, Shimoda N, Akao T, Sato K, Habuchi T, Suzuki T, and Kato T (2001) Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration, Int J Urol 8:353-358.
19. Shimomura M, Masuda S, Saito H, Sakamoto S, Uemoto S, Tanaka K, and Inui K (2002) Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J Surg Res 103:215-222.
20. Squifflet JP, Bäckman L, Claesson K, Dietl K, Ekberg H, Forsythe, Kunzendorf U, Heemann U, Land W, Morales JM, et al. (2001) Dose optimization of Mycophenolate Mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 72:63-69.
21. Tada H, Satoh S, Iinuma M, Shimoda N, Murakami M, Hayase Y, Kato T, and Suzuki T (2003) Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 43:859-865.
22. Tamura S, Ohike A, Ibuki R, Amidon GL, and Yamashita S (2002) Tacrolimus is a class II low-solubility high-permeability drag: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 91:719-729,
23. Tamura S, Tokunaga Y, Ibuki R, Amidon GL, Sezaki H, and Yamashita S (2003) The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharmacol Exp Ther 306:310-316.
24. Tuteja S, Alloway R, Johnson J, and Gaber A (2001) The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71:1303-1307.
25. van Duijnhoven E, Christiaans M, Undre N, Stevenson P, and van Hooff J (1998) The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. Transplant Proc 30:1268-1270.
26. Venkataramanan R. Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J. Lever J, Burckart G, and Starzl T (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404-430.
27. Verleden G, Besse T, and Maes B (2002) Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. Transplantation 73:1974-1976.
28. Yamashita K, Nakate T, Okimoto K, Ohike A. Tokunaga Y, Ibuki R, Higaki K, and Kimura T (2003) Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 267:79-91.